About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Its CABA™ platform encompasses two strategies — CARTA (CD19-CAR T cells for autoimmunity), with lead candidate rese-cel, and CAART (chimeric autoantibody receptor T cells) — targeting conditions such as lupus, myositis, systemic sclerosis, and pemphigus vulgaris. The company was founded in 2017 and went public on Nasdaq in October 2019.
Company details
Funding
Total raised
$88.3M
Last stage
Public
Investors
Founders
Steven Nichtberger
MD; has served as CEO, President, and Chairman of Cabaletta Bio since its founding in 2017. Also a senior fellow and professor of practice at the Wharton School of the University of Pennsylvania. Previously founding CEO of Tengion and held roles at Merck.
LinkedInMichael Milone
MD, PhD; Penn physician-scientist and co-inventor of Kymriah, the first FDA-approved CAR T cell therapy. Serves as co-chair of Cabaletta's Scientific Advisory Board.
Aimee Payne
MD, PhD; Penn physician-scientist and professor of Dermatology. Lead physician in the Autoimmune Blistering Clinic at Penn. Serves as co-chair of Cabaletta's Scientific Advisory Board.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.